NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 2009
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 2008
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 2007
NEWS Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine ByOncoscience 13. October 2007
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 2007
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 2007
NEWS YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data ByOncoscience 30. September 2005
NEWS YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma ByOncoscience 1. March 2005
